Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, Oct. 5, 2021 at 8:00 a.m. ET.
The live webcast will be available in the investor section of the company's website at The webcast will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Chelcie Lister
THRUST Strategic Communications
Media:
Dan Budwick
1AB
